Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TAC01-HER2 |
Synonyms | |
Therapy Description |
TAC01-HER2 are autologous T-lymphocytes engineered to express an ERBB2 (HER2) T-Cell Antigen-Coupler (TAC), which leads to activation and targeting of T-lymphocytes to ERBB2 (HER2)-positive tumor cells, potentially resulting in inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr CT247). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAC01-HER2 | TAC 01-HER2|TAC-01-HER2|TAC-engineered T Cells TAC01-HER2 | TAC01-HER2 are autologous T-lymphocytes engineered to express an ERBB2 (HER2) T-Cell Antigen-Coupler (TAC), which leads to activation and targeting of T-lymphocytes to ERBB2 (HER2)-positive tumor cells, potentially resulting in inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr CT247). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|